Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
J Oncol Pharm Pract
; 23(2): 152-156, 2017 Mar.
Article
en En
| MEDLINE
| ID: mdl-26786028
ABSTRACT
Carfilzomib is a proteasome inhibitor and immunomodulator used to treat patients with multiple myeloma who have disease progression refractory to bortezomib. The difference in agents is that carfilzomib is an irreversible inhibitor of 20 s proteasome. The most common side effects of carfilzomib are fatigue, nausea, diarrhea, anemia, thrombocytopenia, dyspnea, and pyrexia. Less frequent side effects include cardiac manifestations for which we will explore with more detail. In this case report, we describe a 70-year-old female with multiple myeloma presenting to the emergency department with complaint of dyspnea. Patient was discovered to be in heart failure with atrioventricular block necessitating placement of a pacemaker.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oligopéptidos
/
Inhibidores de Proteasoma
/
Bloqueo Cardíaco
/
Insuficiencia Cardíaca
/
Mieloma Múltiple
/
Antineoplásicos
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
J Oncol Pharm Pract
Asunto de la revista:
FARMACIA
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM